Main Menu

Inhibrx, Inc.


Rigrodsky Law, P.A. is investigating Inhibrx, Inc. (“Inhibrx”) regarding possible breaches of fiduciary duties and other violations of law related to Inhibrx’s agreement to be acquired by Sanofi. Under the terms of the agreement, Inhibrx shareholders will receive $30.00 per share in cash, a contingent value right of $5.00, conditioned upon the achievement of a regulatory milestone, and 0.25 shares of a new publicly traded company that will retain Inhibrx's non-INBRX-101 assets.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 07/17/2024

* Indicates a required field.

Back to Page